泛昔洛韦联合外用重组人干扰素α-2b治疗带状疱疹的临床效果

Clinical effect of famciclovir combined with external application of recombinant human interferonα-2b in the treatment of herpes zoster

目的探讨泛昔洛韦联合外用重组人干扰素α-2b治疗带状疱疹的临床效果。方法将120例带状疱疹患者根据单双号随机化分组法分为对照组(60例,泛昔洛韦)与观察组(60例,泛昔洛韦联合外用重组人干扰素α-2b)。比较两组的临床效果。结果治疗后7 d,两组的P物质水平、临床症状评分、VAS评分、IgM、IgG、IgE、IgA水平均降低,且观察组低于对照组(P<0.05)。观察组的止疱时间、水疱完全消失时间、开始结痂时间及痊愈时间均短于对照组(P<0.05)。观察组的治疗总有效率高于对照组,随访3、5个月的复发率均低于对照组(P<0.05)。结论泛昔洛韦联合外用重组人干扰素α-2b治疗带状疱疹的临床效果显著。

Objective To explore the clinical effect of famciclovir combined with external application of recombinant human interferonα-2b in the treatment of herpes zoster.Methods A total of 120 patients with herpes zoster were divided into control group(60 cases,famciclovir)and observation group(60 cases,famciclovir combined with external application of recombinant human interferonα-2b)by the single and even number randomized grouping method.The clinical effects of the two groups were compared.Results At 7 d after treatment,the substance P level,clinical symptom score,VAS score,IgM,IgG,IgE and IgA levels in the two groups decreased,and those in the observation group were lower than the control group(P<0.05).The blister stopping time,blister completely disappearing time,scab forming time and healing time in the observation group were shorter than those in the control group(P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group,the recurrence rate at 3 and 5 months of follow-up were lower than those in the control group(P<0.05).Conclusion Famciclovir combined with external application of recombinant human interferonα-2b in the treatment of herpes zoster has significant clinical effect.